




The relative strengths and weaknesses of Progenics Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Progenics Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 147% points. The greatest weakness of Progenics Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 21% points.

The company's Economic Capital Ratio, given in the ranking table, is 339%, being 119% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	67,467
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,662
Liabilities, Non-Current	1,078
Other Assets	5,442
Other Compr. Net Income	8.0
Other Expenses	2,993
Other Liabilities	0
Other Net Income	60
Other Revenues	14,048
Property and Equipment	3,399
Research and Development	31,840
Selling, General and Administrative Expense	14,706

Output Variable	Value in 1000 USD
Assets	76,308
Liabilities	9,740
Expenses	49,539
Revenues	14,048
Stockholders Equity	66,568
Net Income	-35,431
Comprehensive Net Income	-35,427
BaseVar	74,852
ECR before LimitedLiability	255%
Economic Capital Ratio	339%